Skip to main content

Table 2 Additional inclusion criteria

From: Tear biomarkers for Alzheimer’s disease screening and diagnosis (the TearAD study): design and rationale of an observational longitudinal multicenter study

Additional inclusion criteria for cognitively healthy controls only

MMSE score 26–30 at baseline

Absence of cognitive complaints or treatment and did not seek help for cognitive complaints in the present moment or the past

Additional inclusion criteria for patients only (SCD/MCI/AD Dementia)

Capable of giving informed consent (MMSE score > 17/30)

Back to article page

BMC Neurology

ISSN: 1471-2377

Contact us